Search Results - "Dayyani, F."

Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer by Dayyani, Farshid, Gallick, Gary E., Logothetis, Christopher J., Corn, Paul G.

“…Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These…”
Get full text

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer by Wainberg, Z., Boland, P., Lieu, C., Dayyani, F., Macarulla, T., Zhang, B., Belanger, B., Moore, Y., Wang, T., Maxwell, F., Dean, A.

Get full text

Analysis of delay in adjuvant chemotherapy in locally advanced rectal cancer by Farzaneh, C. A., Pigazzi, A., Duong, W. Q., Carmichael, J. C., Stamos, M. J., Dekhordi-Vakil, F., Dayyani, F., Zell, J. A., Jafari, M. D.

“…Background Adjuvant chemotherapy (AC) after neoadjuvant chemoradiation and surgical resection has been the standard of care for locally advanced rectal cancer…”
Get full text

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) by Dragovich, T., Laheru, D., Dayyani, F., Bolejack, V., Smith, L., Seng, J., Burris, H., Rosen, P., Hidalgo, M., Ritch, P., Baker, A. F., Raghunand, N., Crowley, J., Von Hoff, D. D.

“…Purpose Vatalanib (PTK 787/ZK22584) is an oral poly-tyrosine kinase inhibitor with strong affinity for platelet-derived growth factor and vascular endothelial…”
Get full text

Predicting Benefit of Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach by Harada, G.K., Park, J., Peterson, N.V., Munjal, A.N., Imagawa, D., Jutric, Z., Dayyani, F., Valerin, J., Hong, D.S., Seyedin, S.N.

“…The role of neoadjuvant elective nodal irradiation (ENI) remains controversial for patients with clinically node-negative (cN0) disease after induction…”
Get full text

P-197 Clinical outcomes in patients with Krukenberg tumors from colorectal cancer by Ostowari, A., Hasjim, B., Yu, J., Nguyen, L., Lim, L., Dayyani, F., Cho, M., Senthil, M., Eng, O.

Get full text

Evaluation of Metastatic Potential in Esophageal and Gastroesophageal Junction (GEJ) Cancer with Adherence to Elective Nodal Volume Guidelines: A Retrospective Analysis of Elective Nodal Irradiation by Lyons, J., Harada, G.K., Yeakel, J., Cho, M., Dayyani, F., Smith, B., Daly, S., Nguyen, N., Keshava, H., Kuo, J.V., Seyedin, S.N.

“…In 2015, expert guidelines on esophageal/GEJ cancer contouring for intensity-modulated radiation therapy (IMRT) were published in IJROBP, which delineate…”
Get full text

Effect of Interval between Neoadjuvant Chemotherapy and Radiation Therapy on Metastasis Risk for Inoperable Non-Metastatic Pancreatic Adenocarcinoma by Seyedin, S.N., Fattah, A., Desai, R., Yeakel, J., Harada, G.K., Dayyani, F., Valerin, J., Elquza, E., Imagawa, D., Jutric, Z., Wolf, R., Kuo, J.V.

“…In inoperable pancreatic cancer patients requiring radiotherapy (RT) after neoadjuvant chemotherapy (CT), there can be delays in starting radiation due to…”
Get full text

Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Patients by Yeakel, J., Kuo, J.V., Hagopian, G., Mahmood, S., Bennett, R., Harris, J.P., Simon, A.B., Healy, E., Fernando, D., Abi-Jaoudeh, N., Dayyani, F., Seyedin, S.N.

Get full text

86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study by He, A.R., Valle, J.W., Lee, C-K., Ikeda, M., Potemski, P., Morizane, C., Cundom, J.E., Tougeron, D., Dayyani, F., Rokutanda, N., Xiong, J., Cohen, G., Oh, D-Y.

Get full text

O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study by He, A., Valle, J., Lee, C., Ikeda, M., Potemski, P., Morizane, C., Cundom, J., Tougeron, D., Dayyani, F., Rokutanda, N., Xiong, J., Cohen, G., Oh, D.

Get full text

1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors by Ku, G., Shen, L., Klempner, S.J., Pan, H., Kratz, J., Liang, X., Deng, Y., Kim, S., Wang, Z., Feller, L., Powderly, J., Dayyani, F., Schneider, R.E., Girda, E., Berlin, J.D., Spencer, K., Nguyen, M.T., Wang, V., Xu, C., Zhu, A.

Get full text

79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study by Vogel, A., Chan, S.L., Furuse, J., Tak, W.Y., Masi, G., Varela, M., Kim, J.H., Tanasanvimon, S., Reig Monzon, M.E., Dayyani, F., Makowsky, M., Marcovitz, M., Negro, A., Abou-Alfa, G.K.

Get full text

319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer by Cohen, S.A., Kasi, P.M., Aushev, V.N., Hanna, D.L., Botta, G.P., Sharif, S., Laliotis, G., Sharma, S., Sharma, V., Alqahtani, A., Chandana, S.R., S. Kang, Chakrabarti, S., Somer, B.G., Kasi, A., Dayyani, F., Malla, M., Jurdi, A., Aleshin, A., Kopetz, S.

Get full text

O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study by Vogel, A., Chan, S., Furuse, J., Tak, W., Masi, G., Varela, M., Kim, J., Tanasanvimon, S., Reig, M., Dayyani, F., Makowsky, M., Marcovitz, M., Negro, A., Abou-Alfa, G.

Get full text

193P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9 by Dean, A., Bekaii-Saab, T., Boland, P.M., Dayyani, F., Mercade, T. Macarulla, Mody, K., Belanger, B., Maxwell, F., Moore, Y., Wang, T., Zhang, B., Wainberg, Z.A.

Get full text

191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study by Dean, A., Bekaii-Saab, T., Boland, P.M., Dayyani, F., Mercade, T. Macarulla, Mody, K., Belanger, B., Maxwell, F., Moore, Y., Thiagalingam, A., Wang, T., Zhang, B., Wainberg, Z.A.

Get full text

1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma by Lordick, F., Chao, J., Buxò, E., van Laarhoven, H.W.M., Lima, C.M.R., Lorenzen, S., Dayyani, F., Heinemann, V., Greil, R., Stienen, S., Shitara, K.

Get full text

1529P First-line (1L) liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels by Dean, A., Bekaii-Saab, T., Boland, P.M., Dayyani, F., Macarulla, T., Mody, K., Belanger, B., Maxwell, F., Moore, Y., Wang, T., Zhang, B., Wainberg, Z.A.

Get full text

Abstract No. 456 Comparing the incidence of radioembolization-induced liver disease between patients with and without hepatic surgery prior to radioembolization by Rupasinghe, M., Ramachandran, V., Al-Khouja, F., Fernando, D., Dayyani, F., Ahmed, K., Macherla, A., Franklin, A., Javan, H., Al-Ghazi, M., Kuo, J., Abi-Jaoudeh, N.

Get full text